A novel ytterbium-169 brachytherapy source and delivery system for use in conjunction with minimally invasive wedge resection of early-stage lung cancer.
OBJECTIVE
To describe a novel source-delivery system for intraoperative brachytherapy in patients with early-stage lung cancer that is readily adaptable to a video-assisted thoracoscopic surgery approach and can be precisely delivered to achieve optimal dose distribution.


METHODS
Radioactive ytterbium-169 ((169)Yb) was sealed within a titanium tube 0.28 mm in diameter and then capped and resealed by titanium wires laser welded to the tube to serve as the legs of a tissue-fastening system. Dose simulations were performed using Monte Carlo computer code (Los Alamos National Laboratory, Los Alamos, NM) to mimic the geometric and elemental compositions of the source, fastening apparatus, and surroundings.


RESULTS
Five test source capsules were subjected to a tensile load to failure. Failure in each capsule occurred in the wire of the fastener leg; there were no weld failures. Monte Carlo simulations and subsequent dose measurement showed the perturbation by the source legs in the deployed (bent over) position to be small (4-5%) for (169)Yb and much less than that for iodine-125 (32%).


CONCLUSIONS
We have developed a (169)Yb brachytherapy source-delivery system that can be used in conjunction with commercially available surgical stapling instruments, facilitates the precise placement of brachytherapy sources relative to the surgical margin, assures the seeds remain fixed in their precise position for the duration of the treatment, overcomes the technical difficulties of manipulating the seeds through the narrow surgical incision associated with video-assisted thoracoscopic surgery, and reduces the radiation dose to the clinicians.
Leonard
Kara Lynne
KL
Department of Radiation Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA. kkerr@tuftsmedicalcenter.org
DiPetrillo
Thomas A
TA
Munro
John J
JJ
Wazer
David E
DE
D001918:Brachytherapy / Q000295:instrumentation*; D003131:Combined Modality Therapy; D019544:Equipment Failure Analysis; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D019060:Minimally Invasive Surgical Procedures / Q000295:instrumentation*; D011474:Prosthesis Design; D019919:Prosthesis Implantation / Q000295:instrumentation*; D011868:Radioisotopes / Q000627:therapeutic use*; D015018:Ytterbium / Q000627:therapeutic use*
D011868:Radioisotopes; D015018:Ytterbium